Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 12, 2006, Pages 1528-1536

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Osaki, Yukio ^b   Oka, Hiroko ^c   Urano, Fumihiro ^d   Kudo, Masatoshi ^e   Matsunaga, Takashi ^f  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; DECARBOXYPROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER STAGING; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

AGED; ALPHA-FETOPROTEINS; BILIRUBIN; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; ELECTROPHORESIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PLANT LECTINS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33845450788     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.09.021     Document Type: Article

References (46)

1. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
2. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
3. Di Bisceglie A.M., Goodman Z.D., Ishak K.G., et al. Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. Hepatology 14 (1991) 969-974
4. Kiyosawa K., Sodeyama T., Tanaka E., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12 (1990) 671-675
5. Brechot C., Jaffredo F., Lagorce D., et al. Impact of HBV, HCV, and GBV-C/HGV on hepatocellular carcinomas in Europe: results of an European concerted action. J Hepatol 29 (1998) 173-183
6. Beasley R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
7. Fleming I.D., Coopers J.S., Henson D.E., et al. AJCC cancer staging manual (1997), Lippincott-Raven, Philadelphia
8. International Union Against Cancer (UICC). Liver. In: Sobin L.H., and Wittekind C.H. (Eds). TNM classification of malignant tumours. 6th ed (2002), Wiley, New York 81-83
9. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28 (1998) 751-755
10. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
11. Chevret S., Trinchet J.-C., Mathieu D., et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31 (1999) 133-141
12. Leung W., Tang A.M., Zee B., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94 (2002) 1760-1769
13. Kudo M., Chung H., Haji S., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40 (2004) 1396-1405
14. Pugh R.N.H., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
15. Tateishi R., Yoshida H., Shiina S., et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54 (2005) 419-425
16. Toyoda H., Kumada T., Kiriyama S., et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4 (2006) 111-117
17. Torzilli G., Minagawa M., Takayama T., et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30 (1999) 889-893
18. Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis 19 (1999) 297-309
19. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. English ed (2003), Kanehara & Co, Ltd, Tokyo, Japan
20. Taketa K., Endo Y., Sekiya C., et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res 53 (1993) 5419-5423
21. Yamashita F., Tanaka M., Satomura S., et al. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinoma. Gastroenterology 111 (1996) 996-1001
22. Mita Y., Aoyagi Y., Yanagi M., et al. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82 (1998) 1643-1648
23. Okuda H., Nakanishi T., Takatsu K., et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85 (1999) 812-818
24. Nomura F., Ishijima M., Kuwa K., et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 94 (1999) 650-654
25. Oka H., Tamori A., Kuroki T., et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19 (1994) 61-66
26. Koda M., Murawaki Y., Mitsuda A., et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 88 (2000) 529-537
27. Tsukuma H., Hiyama T., Tanaka S., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328 (1993) 1797-1801
28. Shimizu K., Taniichi T., Satomura S., et al. Establishment of assay kits for determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis. Clin Chim Acta 214 (1993) 3-12
29. Taketa K., Endo Y., Sekiya C., et al. A collaborative study for the evaluation of lectin-reactive α-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53 (1993) 5419-5423
30. Okuda H., Nakanishi T., Takatsu K., et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for α-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 17 (2002) 772-778
31. Weitz I.C., and Liebman H.A. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 18 (1993) 990-997
32. Fujiyama S., Izuno K., Gohshi K., et al. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 36 (1991) 1787-1792
33. Okuda H., Nakanishi T., Takatsu K., et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathological features of solitary hepatocellular carcinoma. Cancer 88 (2000) 544-549
34. Kaplan E.L., and Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 53 (1958) 457-481
35. Petro R., and Pike M.C. Conservation of the approximation (0-E2)/E in the log rank test for survival data on tumor incidence data. Biometrics 29 (1973) 579-584
36. Cox D. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
37. Akaike H. A new look at statistical model identification. IEEE Transactions on Automatic Control AU-19 (1974) 716-722
38. Stone M. Akaike's criteria. In: Armitage P., and Colton T. (Eds). Encyclopedia of biostatistics (1998), Wiley, Chichester, UK 123-124
39. Murakami T., Oi H., Hori M., et al. Helical CT during arterial portography and hepatic arteriography for detecting hypervascular hepatocellular carcinoma. Am J Roentgenol 169 (1997) 131-135
40. Imai Y., Murakami T., Yoshida S., et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 32 (2000) 205-212
41. Berrington de Gonzalez A., and Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 363 (2004) 345-351
42. Nakashima O., Sugihara S., Kage M., et al. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margin. Hepatology 22 (1995) 101-105
43. Bruix J., Sherman M., Practice Guidelines Committee, and American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
44. Toyoda H., Kumada T., Kiriyama S., et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 100 (2004) 2415-2421
45. Huo T.I., Lee S.D., and Wu J.C. Staging for hepatocellular carcinoma: look for a perfect classification system. J Hepatol 40 (2004) 1041-1042
46. Huo T.I., and Huang Y.H. Staging for hepatocellular carcinoma: treatment strategy matters. Hepatology 41 (2005) 678